Free Trial

Beam Therapeutics (BEAM) Competitors

Beam Therapeutics logo
$25.96 +0.17 (+0.64%)
As of 10:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BEAM vs. CRSP, DNLI, EDIT, NTLA, TWST, VCYT, QGEN, BBIO, ELAN, and VRNA

Should you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Twist Bioscience (TWST), Veracyte (VCYT), Qiagen (QGEN), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "medical" sector.

Beam Therapeutics vs. Its Competitors

Beam Therapeutics (NASDAQ:BEAM) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Beam Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500.

Beam Therapeutics has a net margin of -661.31% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat Beam Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Beam Therapeutics-661.31% -43.15% -31.06%
CRISPR Therapeutics -1,229.43%-20.05%-17.09%

CRISPR Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$63.52M41.34-$376.74M-$4.50-5.77
CRISPR Therapeutics$37.31M165.95-$366.25M-$5.43-12.54

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 3.5% of Beam Therapeutics shares are held by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Beam Therapeutics presently has a consensus price target of $45.92, indicating a potential upside of 76.91%. CRISPR Therapeutics has a consensus price target of $72.59, indicating a potential upside of 6.63%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
2.94
CRISPR Therapeutics
2 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.42

In the previous week, CRISPR Therapeutics had 24 more articles in the media than Beam Therapeutics. MarketBeat recorded 31 mentions for CRISPR Therapeutics and 7 mentions for Beam Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.61 beat Beam Therapeutics' score of 0.58 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beam Therapeutics
0 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CRISPR Therapeutics
11 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Beam Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Beam Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BEAM vs. The Competition

MetricBeam TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.63B$3.42B$6.10B$10.49B
Dividend YieldN/A2.29%5.73%4.78%
P/E Ratio-5.7723.0484.6327.17
Price / Sales41.34484.44608.51132.45
Price / CashN/A46.9737.8662.13
Price / Book2.9310.5112.356.62
Net Income-$376.74M-$52.47M$3.33B$276.88M
7 Day Performance-1.39%3.06%2.11%1.49%
1 Month Performance15.61%15.52%9.40%4.79%
1 Year Performance6.59%13.77%73.46%36.32%

Beam Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BEAM
Beam Therapeutics
3.4357 of 5 stars
$25.96
+0.6%
$45.92
+76.9%
-3.4%$2.63B$63.52M-5.77510
CRSP
CRISPR Therapeutics
2.2415 of 5 stars
$70.19
+3.6%
$71.50
+1.9%
+39.7%$6.38B$37.31M-12.93460Trending News
Analyst Forecast
Insider Trade
Analyst Revision
Gap Up
DNLI
Denali Therapeutics
4.1674 of 5 stars
$15.22
-1.3%
$33.50
+120.1%
-39.6%$2.23B$330.53M-5.44430News Coverage
Analyst Revision
EDIT
Editas Medicine
4.1848 of 5 stars
$3.80
-3.1%
$5.10
+34.2%
+14.8%$341.70M$32.31M-1.33230Gap Down
NTLA
Intellia Therapeutics
4.171 of 5 stars
$20.54
+2.9%
$27.95
+36.1%
+21.0%$2.20B$57.88M-4.38600Gap Down
TWST
Twist Bioscience
3.8478 of 5 stars
$31.85
+2.5%
$48.90
+53.5%
-31.8%$1.92B$312.97M-21.97990Analyst Revision
VCYT
Veracyte
3.6891 of 5 stars
$36.04
+0.1%
$40.90
+13.5%
+3.1%$2.84B$445.76M109.22790News Coverage
QGEN
Qiagen
4.1228 of 5 stars
$46.99
+0.4%
$49.40
+5.1%
+14.5%$10.45B$1.98B27.765,765
BBIO
BridgeBio Pharma
4.4949 of 5 stars
$54.61
+3.3%
$63.94
+17.1%
+108.9%$10.44B$221.90M-13.35400Positive News
Analyst Revision
ELAN
Elanco Animal Health
2.5478 of 5 stars
$20.68
+0.2%
$18.33
-11.3%
+54.6%$10.27B$4.44B24.059,000Analyst Revision
VRNA
Verona Pharma PLC American Depositary Share
1.536 of 5 stars
$106.91
+0.1%
$109.00
+2.0%
N/A$9.21B$42.28M-107.9930Positive News

Related Companies and Tools


This page (NASDAQ:BEAM) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners